Australian IAQ, deep clean and corrosion protection expert Aeris Environmental has secured extended residual claims from the Therapeutic Goods Administration for its Aeris Active disinfectant cleaner.
The on-label claims now include “Residual COVID-19 kill for up to seven days” and “Residual antibacterial for up to 30 days (or 200 touches) against gram-negative E. coli and gram-positive S. aureus”.
The claims are the result of extensive independent scientific testing and validation studies at accredited NATA laboratory, Eurofins AMS. These demonstrated that Aeris Active has the ability to kill COVID-19 for up to a week on surfaces, together with an approved residual antibacterial efficacy for up to 30 days (or 200 touches) against the test organisms of gram-negative E. coli and gram-positive S. aureus.
Aeris says it has now established a new “gold standard” in environmental hygiene, with products that are effective in a single-step application, that have been tested in the TGA Disinfectant Test under Option B “dirty conditions”, and meet hospital-grade disinfectant standards.
“I am proud that Aeris is able to offer its proprietary dual-active technology, supported with outstanding ‘on-label’ claims consistent with an approval set that we are developing internationally,” says Aeris Environmental CEO Peter Bush.
“This recognition confirms the ‘real world’ performance of our products, and I am pleased that this Australian developed, manufactured and patented technology is being recognised globally for its unique position of ‘clean-green-protect’.
“It is imperative that during this global pandemic products gain the trust of the consumer and deliver on the promise of proven performance.”